Overview Financials News + Filings Key Docs Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| | 10-K | 10-K | 10-K | Source |
| Revenues: |
| Oncology | 124.8 | 46.7 | | |
| Radiology | 624.8 | 374.4 | 245.6 | |
| Total revenues | 749.6 | 421.1 | 245.6 | 247.4 |
| Revenue growth [+] | 78.0% | 71.4% | -0.7% | |
| Oncology | 167.3% | | | |
| Radiology | 66.9% | 52.4% | | |
| Cost of goods sold | 608.4 | 356.4 | 205.6 | 15.6 |
| Gross profit | 141.3 | 64.7 | 40.0 | 231.8 |
| Gross margin | 18.8% | 15.4% | 16.3% | 93.7% |
| Selling, general and administrative | 777.7 | 407.5 | 220.6 | 208.0 |
| Other operating expenses | -764.5 | -422.6 | -224.2 | -15.7 |
| EBITDA [+] | 128.0 | 79.8 | 43.5 | 15,626.7 |
| EBITDA growth | 60.4% | 83.4% | -99.7% | |
| EBITDA margin | 17.1% | 19.0% | 17.7% | 6315.5% |
| Depreciation | 77.5 | 36.4 | 17.1 | 15,587.2 |
| EBITA | 50.5 | 43.4 | 26.5 | 39.5 |
| EBITA margin | 6.7% | 10.3% | 10.8% | 16.0% |
| Amortization of intangibles | 20.7 | 8.5 | | |
| EBIT [+] | 29.8 | 34.9 | 26.5 | 39.5 |
| EBIT growth | -14.6% | 31.9% | -33.1% | |
| EBIT margin | 4.0% | 8.3% | 10.8% | 16.0% |
| Non-recurring items [+] | 57.9 | 21.3 | 1.5 | 3.4 |
| Asset impairment | 47.2 | | | |
| Unusual expense | -0.9 | -0.3 | 0.4 | |
| Interest expense | 118.0 | 62.6 | 32.8 | 20.8 |
| Interest expense | 118.0 | 62.6 | 32.8 | 20.8 |
| Other income (expense), net [+] | 2.9 | -16.2 | -25.8 | |
| Other | -3.6 | -4.0 | 22.4 | |
| Pre-tax income | -143.2 | -65.2 | -33.6 | 15.4 |
| Income taxes | 8.4 | -30.4 | 0.6 | 3.7 |
| Tax rate | | 46.6% | | 24.3% |
| Minority interest | 5.2 | 8.5 | 2.6 | 2.2 |
| Net income | -156.8 | -43.3 | -36.7 | 9.4 |
| Net margin | -20.9% | -10.3% | -15.0% | 3.8% |
| |
| Basic EPS [+] | ($1.75) | ($0.56) | ($0.52) | $0.14 |
| Growth | 211.0% | 7.5% | -474.4% | |
| Diluted EPS [+] | ($1.75) | ($0.56) | ($0.52) | $0.14 |
| Growth | 211.0% | 7.5% | -474.4% | |
| |
| Shares outstanding (basic) [+] | 89.5 | 76.8 | 70.1 | 67.3 |
| Growth | 16.4% | 9.6% | 4.1% | |
| Shares outstanding (diluted) [+] | 89.5 | 76.8 | 70.1 | 67.3 |
| Growth | 16.4% | 9.6% | 4.1% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|